Class IV Heart Failure Patients Almost Included In MCAC Coverage Vote
This article was originally published in The Gray Sheet
Executive Summary
Medtronic anticipates October completion of its Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), with results to be presented at the American College of Cardiology meeting in spring 2004
You may also be interested in...
Medtronic’s SCD-HeFT
Sudden Cardiac Death in Heart Failure Trial completes follow-up phase with minimum of 30 months and average of 40 months follow-up, the firm says. Results are slated for release in the first quarter of 2004. The 2,521-patient trial, begun in 1997, compares ICD-implanted patient arrhythmia and mortality rates with drug and placebo arms in moderate heart failure patients at high risk for sudden cardiac arrest (1"The Gray Sheet" Feb. 17, 2003, p. 6)...
Medtronic’s SCD-HeFT
Sudden Cardiac Death in Heart Failure Trial completes follow-up phase with minimum of 30 months and average of 40 months follow-up, the firm says. Results are slated for release in the first quarter of 2004. The 2,521-patient trial, begun in 1997, compares ICD-implanted patient arrhythmia and mortality rates with drug and placebo arms in moderate heart failure patients at high risk for sudden cardiac arrest (1"The Gray Sheet" Feb. 17, 2003, p. 6)...
Tunis Presses NIH To Share ICD Study Findings; Dollens Claims Data Irrelevant
CMS will contact the National Heart, Lung & Blood Institute within the next two weeks to try to determine why SCD-HeFT study patients who met the MADIT-II trial criteria were not switched to the active ICD treatment arm